Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in R/R Mature T- and NK-cell Neoplasms
NCT03493451Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2018
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of tislelizumab in Extranodal NK/T-cell lymphoma (ENKTL), peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), mycosis fungoides (MF), sponsored by BeiGene. Started Apr 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03493451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493451.